Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Gains from Investment Securities (2016 - 2025)

Vanda Pharmaceuticals' Gains from Investment Securities history spans 16 years, with the latest figure at $5.2 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 188.77% year-over-year to $5.2 million; the TTM value through Dec 2025 reached $915000.0, up 490.32%, while the annual FY2025 figure was $915000.0, 490.32% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $5.2 million at Vanda Pharmaceuticals, up from -$1.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.2 million in Q4 2025 and bottomed at -$1.9 million in Q1 2025.
  • The 5-year median for Gains from Investment Securities is -$556000.0 (2021), against an average of -$274157.9.
  • The largest YoY upside for Gains from Investment Securities was 188.77% in 2025 against a maximum downside of 187.78% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at -$506000.0 in 2021, then tumbled by 66.8% to -$844000.0 in 2022, then skyrocketed by 180.21% to $677000.0 in 2023, then soared by 165.58% to $1.8 million in 2024, then surged by 188.77% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Gains from Investment Securities are $5.2 million (Q4 2025), -$1.4 million (Q3 2025), and -$1.0 million (Q2 2025).